;PMID: 9464645 ;source_file_2836.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..42] = [t:0..42] ;1)sentence:[e:48..212] = [t:48..212] ;2)section:[e:216..254] = [t:216..254] ;3)section:[e:258..353] = [t:258..353] ;4)sentence:[e:357..896] = [t:357..896] ;5)sentence:[e:898..1082] = [t:898..1082] ;6)sentence:[e:1083..1266] = [t:1083..1266] ;7)section:[e:1270..1314] = [t:1270..1314] ;section 0 Span:0..42 ;Neurosci Lett. 1997 Nov 28;238(1-2):21-4. (SEC (FRAG (NNP:[0..8] Neurosci) (NNP:[9..13] Lett) (.:[13..14] .) (CD:[16..20] 1997) (NNP:[21..24] Nov) (CD:[25..27] 28) (::[27..28] ;) (CD:[28..31] 238) (-LRB-:[31..32] -LRB-) (NN:[32..35] 1-2) (-RRB-:[35..36] -RRB-) (::[36..37] :) (CD:[37..41] 21-4) (.:[41..42] .))) ;sentence 1 Span:48..212 ;Effect of lipopolysaccharide on the gene expression of the enzymes involved ;in tetrahydrobiopterin de novo biosynthesis in murine neuroblastoma cell ;line N1E-115. ;[179..192]:malignancy-type:"neuroblastoma" (SENT (NP-HLN (NP (NN:[48..54] Effect)) (PP (IN:[55..57] of) (NP (NN:[58..76] lipopolysaccharide))) (PP (IN:[77..79] on) (NP (NP (DT:[80..83] the) (NN:[84..88] gene) (NN:[89..99] expression)) (PP (IN:[100..102] of) (NP (NP (DT:[103..106] the) (NNS:[107..114] enzymes)) (VP (VBN:[115..123] involved) (NP (-NONE-:[123..123] *)) (PP-CLR (IN:[124..126] in) (NP (NP (NN:[128..147] tetrahydrobiopterin) (ADJP (FW:[148..150] de) (FW:[151..155] novo)) (NN:[156..168] biosynthesis)) (PP (IN:[169..171] in) (NP (NML (JJ:[172..178] murine) (NN:[179..192] neuroblastoma) (NN:[193..197] cell) (NN:[198..202] line)) (NN:[204..211] N1E-115)))))))))) (.:[211..212] .))) ;section 2 Span:216..254 ;Mori K, Nakashima A, Nagatsu T, Ota A. (SEC (FRAG (NNP:[216..220] Mori) (NNP:[221..222] K) (,:[222..223] ,) (NNP:[224..233] Nakashima) (NNP:[234..235] A) (,:[235..236] ,) (NNP:[237..244] Nagatsu) (NNP:[245..246] T) (,:[246..247] ,) (NNP:[248..251] Ota) (NNP:[252..253] A) (.:[253..254] .))) ;section 3 Span:258..353 ;Department of Physiology, School of Medicine, Fujita Health University, ;Toyoake, Aichi, Japan. (SEC (FRAG (NNP:[258..268] Department) (IN:[269..271] of) (NNP:[272..282] Physiology) (,:[282..283] ,) (NNP:[284..290] School) (IN:[291..293] of) (NNP:[294..302] Medicine) (,:[302..303] ,) (NNP:[304..310] Fujita) (NNP:[311..317] Health) (NNP:[318..328] University) (,:[328..329] ,) (NNP:[330..337] Toyoake) (,:[337..338] ,) (NNP:[340..345] Aichi) (,:[345..346] ,) (NNP:[347..352] Japan) (.:[352..353] .))) ;sentence 4 Span:357..896 ;The amounts of messenger RNA for three enzymes, namely guanosine triphosphate ; (GTP) cyclohydrolase 1,6-pyruvoyltetrahydropterin synthase, and sepiapterin ;reductase, all of which are involved in the de novo biosynthesis of ;(6R)-L-erythrodihydroxypropyl-2-amino-4-hydroxy-5,6,7,8-tetrahydro pteridine ;(BH4) from GTP, were measured quantitatively in murine neuroblastoma cell ;line N1E-115 by the competitive polymerase chain reaction (PCR) technique ;after reverse transcription using a heterologous DNA fragment as an internal ;standard. ;[412..456]:gene-protein:"guanosine triphosphate (GTP) cyclohydrolase" ;[457..494]:gene-protein:"1,6-pyruvoyltetrahydropterin synthase" ;[500..522]:gene-protein:"sepiapterin reductase" ;[715..728]:malignancy-type:"neuroblastoma" ;[767..777]:gene-protein:"polymerase" (SENT (S (NP-SBJ-2 (NP (DT:[357..360] The) (NNS:[361..368] amounts)) (PP (IN:[369..371] of) (NP (NP (NN:[372..381] messenger) (NN:[382..385] RNA)) (PP (IN:[386..389] for) (NP (NP (CD:[390..395] three) (NNS:[396..403] enzymes)) (,:[403..404] ,) (NP (ADVP (RB:[405..411] namely)) (NP (NML (NML (NN:[412..421] guanosine) (NN:[422..434] triphosphate)) (NML (-LRB-:[436..437] -LRB-) (NN:[437..440] GTP) (-RRB-:[440..441] -RRB-))) (NN:[442..456] cyclohydrolase)) (NP (NN:[457..485] 1,6-pyruvoyltetrahydropterin) (NN:[486..494] synthase)) (,:[494..495] ,) (CC:[496..499] and) (NP (NN:[500..511] sepiapterin) (NN:[513..522] reductase)) (,:[522..523] ,) (SBAR (WHNP-1 (NP (DT:[524..527] all)) (WHPP (IN:[528..530] of) (WHNP (WDT:[531..536] which)))) (S (NP-SBJ-1 (-NONE-:[536..536] *T*)) (VP (VBP:[537..540] are) (VP (VBN:[541..549] involved) (NP-1 (-NONE-:[549..549] *)) (PP-CLR (IN:[550..552] in) (NP (NP (DT:[553..556] the) (ADJP (FW:[557..559] de) (FW:[560..564] novo)) (NN:[565..577] biosynthesis)) (PP (IN:[578..580] of) (NP (NN:[582..648] -LRB-6R-RRB--L-erythrodihydroxypropyl-2-amino-4-hydroxy-5,6,7,8-tetrahydro) (NN:[649..658] pteridine) (PRN (-LRB-:[660..661] -LRB-) (NP (NN:[661..664] BH4)) (-RRB-:[664..665] -RRB-)))) (PP (IN:[666..670] from) (NP (NN:[671..674] GTP))))))))))))))) (,:[674..675] ,) (VP (VBD:[676..680] were) (VP (VBN:[681..689] measured) (NP-2 (-NONE-:[689..689] *)) (ADVP (RB:[690..704] quantitatively)) (PP-LOC (IN:[705..707] in) (NP (NML (JJ:[708..714] murine) (NN:[715..728] neuroblastoma) (NN:[729..733] cell) (NN:[734..738] line)) (NN:[740..747] N1E-115))) (PP-MNR (IN:[748..750] by) (NP (DT:[751..754] the) (JJ:[755..766] competitive) (NML (NML (NN:[767..777] polymerase) (NN:[778..783] chain) (NN:[784..792] reaction)) (NML (-LRB-:[793..794] -LRB-) (NN:[794..797] PCR) (-RRB-:[797..798] -RRB-))) (NN:[799..808] technique))) (PP-TMP (IN:[809..814] after) (NP (JJ:[816..823] reverse) (NN:[824..837] transcription))) (S-MNR (NP-SBJ (-NONE-:[837..837] *)) (VP (VBG:[838..843] using) (NP (DT:[844..845] a) (JJ:[846..858] heterologous) (NN:[859..862] DNA) (NN:[863..871] fragment)) (PP (IN:[872..874] as) (NP (DT:[875..877] an) (JJ:[878..886] internal) (NN:[887..895] standard))))))) (.:[895..896] .))) ;sentence 5 Span:898..1082 ;Twenty-four hour activation of this cell line with 1 microg/ml ;lipopolysaccharide resulted in statistically significant increases in the ;amounts of the messages of all three enzymes. ;[1064..1081]:gene-protein:"all three enzymes" (SENT (S (NP-SBJ (NP (NML (CD:[898..909] Twenty-four) (NN:[910..914] hour)) (NN:[915..925] activation)) (PP (IN:[926..928] of) (NP (DT:[929..933] this) (NN:[934..938] cell) (NN:[939..943] line))) (PP (IN:[944..948] with) (NP (NML (NML (CD:[949..950] 1) (NN:[951..957] microg)) (PP (SYM:[957..958] /) (NP (NN:[958..960] ml)))) (NN:[962..980] lipopolysaccharide)))) (VP (VBD:[981..989] resulted) (PP-CLR (IN:[990..992] in) (NP (NP (ADJP (RB:[993..1006] statistically) (JJ:[1007..1018] significant)) (NNS:[1019..1028] increases)) (PP (IN:[1029..1031] in) (NP (NP (DT:[1032..1035] the) (NNS:[1037..1044] amounts)) (PP (IN:[1045..1047] of) (NP (NP (DT:[1048..1051] the) (NNS:[1052..1060] messages)) (PP (IN:[1061..1063] of) (NP (DT:[1064..1067] all) (CD:[1068..1073] three) (NNS:[1074..1081] enzymes)))))))))) (.:[1081..1082] .))) ;sentence 6 Span:1083..1266 ;Our data suggest that lipopolysaccharide can activate the intrinsic pathway ;resulting in the enhanced gene expression of these three enzymes in ;neuron-derived cells such as N1E-115. ;[1206..1225]:gene-protein:"these three enzymes" (SENT (S (NP-SBJ (PRP$:[1083..1086] Our) (NNS:[1087..1091] data)) (VP (VBP:[1092..1099] suggest) (SBAR (IN:[1100..1104] that) (S (NP-SBJ (NN:[1106..1124] lipopolysaccharide)) (VP (MD:[1125..1128] can) (VP (VB:[1129..1137] activate) (NP (NP (DT:[1138..1141] the) (JJ:[1142..1151] intrinsic) (NN:[1152..1159] pathway)) (VP (VBG:[1160..1169] resulting) (PP-CLR (IN:[1170..1172] in) (NP (NP (DT:[1173..1176] the) (VBN:[1177..1185] enhanced) (NN:[1187..1191] gene) (NN:[1192..1202] expression)) (PP (IN:[1203..1205] of) (NP (DT:[1206..1211] these) (CD:[1212..1217] three) (NNS:[1218..1225] enzymes))))) (PP-LOC (IN:[1226..1228] in) (NP (NP (ADJP (NN:[1229..1235] neuron) (HYPH:[1235..1236] -) (VBN:[1236..1243] derived)) (NNS:[1244..1249] cells)) (PP (JJ:[1250..1254] such) (IN:[1255..1257] as) (NP (NN:[1258..1265] N1E-115)))))))))))) (.:[1265..1266] .))) ;section 7 Span:1270..1314 ;PMID: 9464645 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1270..1274] PMID) (::[1274..1275] :) (CD:[1276..1283] 9464645) (NN:[1284..1285] -LSB-) (NNP:[1285..1291] PubMed) (::[1292..1293] -) (NN:[1294..1301] indexed) (IN:[1302..1305] for) (NNP:[1306..1313] MEDLINE) (-RRB-:[1313..1314] -RSB-)))